Litcius/Paper detail

Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study

Manon De Vries-Brilland, Marine Gross‐Goupil, Valérie Seegers, Elouen Boughalem, Benoit Beuselinck, Constance Thibault, Christine Chevreau, Sylvain Ladoire, Philippe Barthélémy, Sylvie Négrier, Delphine Borchiellini, Olivier Huillard, Lionnel Geoffrois, Gwénaëlle Gravis, Carolina Saldana, Antoine Thiery-Vuillemin, Bernard Escudier, Alain Ravaud, Laurence Albigès

2020European Journal of Cancer24 citationsDOI

Topics & Concepts

DiscontinuationMedicineInternal medicineAdverse effectPapillary renal cell carcinomasOncologyClinical endpointRenal cell carcinomaRetrospective cohort studyHazard ratioProgressive diseaseConfidence intervalGastroenterologyDiseaseClinical trialRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis
Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study | Litcius